U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C2H6N4O4S
Molecular Weight 182.158
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of UREA, N,N''-SULFONYLBIS-

SMILES

NC(=O)NS(=O)(=O)NC(N)=O

InChI

InChIKey=NRCPVGIMMWPWGT-UHFFFAOYSA-N
InChI=1S/C2H6N4O4S/c3-1(7)5-11(9,10)6-2(4)8/h(H3,3,5,7)(H3,4,6,8)

HIDE SMILES / InChI

Molecular Formula C2H6N4O4S
Molecular Weight 182.158
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Approval Year

PubMed

PubMed

TitleDatePubMed
Identification and pharmacological correction of a membrane trafficking defect associated with a mutation in the sulfonylurea receptor causing familial hyperinsulinism.
2001-09-21
Identification and properties of a novel intracellular (mitochondrial) ATP-sensitive potassium channel in brain.
2001-09-07
The Arabidopsis thaliana ABC protein superfamily, a complete inventory.
2001-08-10
Nicorandil enhances cardiac endothelial nitric oxide synthase expression via activation of adenosine triphosphate-sensitive K channel in rat.
2001-08
Serum nonesterified fatty acids are related with carotid atherosclerotic plaque in nonobese nonhypertensive Japanese type 2 diabetic patients.
2001-08
Glucagon-like peptide-1 infusion must be maintained for 24 h/day to obtain acceptable glycemia in type 2 diabetic patients who are poorly controlled on sulphonylurea treatment.
2001-08
Utilization of oral hypoglycemic agents in a drug-insured U.S. population.
2001-08
Acute and short-term administration of a sulfonylurea (gliclazide) increases pulsatile insulin secretion in type 2 diabetes.
2001-08
Behavioral and olfactory responses to prochloraz, bentazone, and nicosulfuron-contaminated flows in goldfish.
2001-08
Is the molecular composition of K(ATP) channels more complex than originally thought?
2001-08
Two new genes from the human ATP-binding cassette transporter superfamily, ABCC11 and ABCC12, tandemly duplicated on chromosome 16q12.
2001-07-25
Molecular physiology of neuronal K-ATP channels (review).
2001-07-21
Pioglitazone hydrochloride in combination with sulfonylurea therapy improves glycemic control in patients with type 2 diabetes mellitus: a randomized, placebo-controlled study.
2001-07
Oral agents for the treatment of type 2 diabetes mellitus: pharmacology, toxicity, and treatment.
2001-07
Relationship between ethnicity and glycemic control, lipid profiles, and blood pressure during the first 9 years of type 2 diabetes: U.K. Prospective Diabetes Study (UKPDS 55).
2001-07
Characterization of a mutant sulfonylurea receptor SUR2B with high affinity for sulfonylureas and openers: differences in the coupling to Kir6.x subtypes.
2001-07
Glimepiride, a novel sulfonylurea, does not abolish myocardial protection afforded by either ischemic preconditioning or diazoxide.
2001-06-26
NADH oxidase activity (NOX) and enlargement of HeLa cells oscillate with two different temperature-compensated period lengths of 22 and 24 minutes corresponding to different NOX forms.
2001-06-20
Molecular structure of the glibenclamide binding site of the beta-cell K(ATP) channel.
2001-06-15
Impact of sulfonylurea receptor 1 genetic variability on non-insulin-dependent diabetes mellitus prevalence and treatment: a population study.
2001-06-01
Effect of repaglinide on cloned beta cell, cardiac and smooth muscle types of ATP-sensitive potassium channels.
2001-06
Management of type 2 diabetes. Evolving strategies for treatment.
2001-06
Application of coupled liquid chromatography-mass spectrometry in photolysis studies of the herbicide triflusulfuron-methyl.
2001-06
Effects of rifampin on the pharmacokinetics and pharmacodynamics of glyburide and glipizide.
2001-06
Unbalanced expression of 11p15 imprinted genes in focal forms of congenital hyperinsulinism: association with a reduction to homozygosity of a mutation in ABCC8 or KCNJ11.
2001-06
Glibenclamide effects on reperfusion-induced malignant arrhythmias and left ventricular mechanical recovery from stunning in conscious sheep.
2001-06
A novel enhancer of insulinotrophic action by high glucose (JTT-608) stimulates insulin secretion from pancreatic beta-cells via a new cellular mechanism.
2001-06
Effect of a series of novel sulphonylthioureas on glucose tolerance in the obese fa/fa Zucker rat.
2001-05-31
Cellular and biophysical evidence for interactions between adenosine triphosphate and P-glycoprotein substrates: functional implications for adenosine triphosphate/drug cotransport in P-glycoprotein overexpressing tumor cells and in P-glycoprotein low-level expressing erythrocytes.
2001-05-19
Effects of sulfonylurea derivatives on ischemia-induced loss of function in the isolated rat heart.
2001-05-04
Oral agents in the management of type 2 diabetes mellitus.
2001-05-01
[Current and future aspects of oral antidiabetic agents in type 2 diabetes].
2001-05
[Diabetology at the threshold of the 21st century].
2001-05
Amaranthus palmeri resistance and differential tolerance of Amaranthus palmeri and Amaranthus hybridus to ALS-inhibitor herbicides.
2001-05
Design, synthesis and biological evaluation of a sulfonylcyanoguanidine as thromboxane A2 receptor antagonist and thromboxane synthase inhibitor.
2001-05
Use of the ligand immunofunctional assay for human insulin-like growth factor ((IGF) binding protein-3 (IGFBP-3) to analyze IGFBP-3 proteolysis and igf-i bioavailability in healthy adults, GH-deficient and acromegalic patients, and diabetics.
2001-05
Insulinoma induced hypoglycemia in a type 2 diabetic patient.
2001-04-30
Degradation of imazosulfuron in soil.
2001-04
[Type 2 diabetes mellitus: Which place for thiazolidinediones in the therapeutic strategy?].
2001-04
[Diabetes mellitus and ischemic cardiopathy: potential effects of the use of sulfonylureas].
2001-04
Interaction of sulfonylurea-conjugated polymer with insulinoma cell line of MIN6 and its effect on insulin secretion.
2001-04
Comments to: Yudkin J, Panahloo A, Stenhouwer C et al. (2000) the influence of improved glycaemic control with insulin and sulphonylureas on acute phase and endothelial markers in type II diabetic subjects. Diabetologia 43: 1099-1106.
2001-04
Comments to: Yudkin J, Panahloo A, Stenhouwer C et al. (2000) the influence of improved glycaemic control with insulin and sulphonylureas on acute phase and endothelial markers in type II diabetic subjects. Diabetologia 43: 1099-1106.
2001-04
Involvement of cytochrome P-450 enzyme activity in the selectivity and safening action of pyrazosulfuron-ethyl.
2001-03
Response of the bacteria and fungi of two soils to the sulfonylurea herbicide cinosulfuron.
2001-03
Clinical significance of the insulin resistance index as assessed by homeostasis model assessment.
2001-02
Effects of atrazine and nicosulfuron on freshwater microalgae.
2001-01
Oral hypoglycemic agents: insulin secretagogues, alpha-glucosidase inhibitors and insulin sensitizers.
2001
Comparison of the effects of three sulfonylureas on in vivo insulin action.
2001
Relationship between plasma soluble thrombomodulin levels and insulin resistance syndrome in type 2 diabetes: a comparison with von Willebrand factor.
2001
Patents
Substance Class Chemical
Created
by admin
on Mon Mar 31 18:49:30 GMT 2025
Edited
by admin
on Mon Mar 31 18:49:30 GMT 2025
Record UNII
M5112OW4K3
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
UREA, N,N''-SULFONYLBIS-
Preferred Name English
Code System Code Type Description
FDA UNII
M5112OW4K3
Created by admin on Mon Mar 31 18:49:30 GMT 2025 , Edited by admin on Mon Mar 31 18:49:30 GMT 2025
PRIMARY
CAS
35507-37-0
Created by admin on Mon Mar 31 18:49:30 GMT 2025 , Edited by admin on Mon Mar 31 18:49:30 GMT 2025
PRIMARY
EPA CompTox
DTXSID00881179
Created by admin on Mon Mar 31 18:49:30 GMT 2025 , Edited by admin on Mon Mar 31 18:49:30 GMT 2025
PRIMARY
PUBCHEM
104818
Created by admin on Mon Mar 31 18:49:30 GMT 2025 , Edited by admin on Mon Mar 31 18:49:30 GMT 2025
PRIMARY